Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

Andrew Smith

Crisis? No problem!

Issues planning & management for pharma spokespeople, by Andrew Smith

Havas Life London

- PMLiVE

UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus

UK human ‘challenge trial’ programme would be a world first

- PMLiVE

Keytruda doubles five-year survival rate in NSCLC

Merck reveals long-term efficacy data for blockbuster immunotherapy

- PMLiVE

Could formulary intelligence be your brand differentiator?

Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch

- PMLiVE

Relief Therapeutics seeks US emergency approval for COVID-19 drug

If granted, EUA would give approval for use in severely ill patients with no other treatment options

- PMLiVE

How COVID-19 is accelerating the threat of antimicrobial resistance

Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

- PMLiVE

Porterhouse Medical strengthens its senior management team

Announcing the well-deserved promotion of Erica Cave

Porterhouse Medical Group

- PMLiVE

Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

Positive interim results presented at 2020 ESMO virtual congress

- PMLiVE

OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020

We are delighted to have won another Bronze Award at the PM Society Digital Awards 2020in the Healthcare Charities & Patient Associations Category for Alexander Devine Children's Hospice Service. READ MORE ABOUT OUR...

OPEN Health

- PMLiVE

AZ/Merck’s Lynparza improves survival in certain prostate cancers

New data released at ESMO 2020 virtual congress shows drug cuts the risk of death

- PMLiVE

Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer

New data from KEYNOTE-590 trial was presented at ESMO 2020 virtual congress

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links